Verici Dx plc (LON:VRCI – Get Free Report)’s stock price hit a new 52-week low on Wednesday . The stock traded as low as GBX 2.82 ($0.04) and last traded at GBX 3.08 ($0.04), with a volume of 433837 shares trading hands. The stock had previously closed at GBX 3.38 ($0.04).
Verici Dx Price Performance
The firm has a market capitalization of £7.15 million, a price-to-earnings ratio of -143.75 and a beta of 1.59. The company has a current ratio of 4.54, a quick ratio of 8.49 and a debt-to-equity ratio of 4.65. The stock’s fifty day moving average price is GBX 5.15 and its two-hundred day moving average price is GBX 6.46.
Verici Dx Company Profile
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
See Also
- Five stocks we like better than Verici Dx
- Overbought Stocks Explained: Should You Trade Them?
- 3 High-Yields Unfazed by the Election: Altria, Truist, Verizon
- P/E Ratio Calculation: How to Assess Stocks
- Q3 Earnings Indicate On Holdings May Outperform Lululemon in 2024
- Dividend Capture Strategy: What You Need to Know
- Cisco Systems Long-Term AI Play Turns a Corner: New Highs Likely
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
